AstraZeneca said that its Lynparza breast cancer drug’s supplemental new application had been accepted and granted Priority Review by the US Food and Drug Administration.
Lynparza is used to treat patients with early breast cancer who have already received chemotherapy either before or after surgery, the company said on Tuesday.
The Anglo-Swedish added the application was based on results from the OlympiA phase 3 trial which showed Lynparza demonstrated a statistically significant improvement in invasive disease-free survival.
